Please assess the completion status of the following clinical trial:

Trial Title: Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven resectable adenocarcinoma of the lower oesophagus and gastric-oesophageal junction~* Tumour stage: T2-3 N0-1 M0, as assessed by endoscopic ultrasound and CT-scan of thorax and abdomen and ultrasound neck region. For the patients treated in this study the gastro-oesophageal junctional tumors will be staged as oesophageal tumors with respect to their lymphnode metastases.~* Age \>18y and written informed consent after at least 4 days of deliberation time from the moment the patient information has been given and has been explained.~* Weight loss \< 10% in 0.5 yr~* WHO performance status 0-1~* No prior radiotherapy or chemotherapy for the adenocarcinoma of the oesophagus~Exclusion Criteria:~* Previous malignancy other than basal cell carcinoma of the skin or local resection for cervical carcinoma in situ.~* Inadequate organ function as defined by:~* Inadequate haematology (Hb \< 5,5 mmol/L (red blood cell transfusions are allowed to increase the Hb at the discretion of the investigator) - neutrophils \< 1,5 109/L -platelets \<100\*109/L),~* Liver enzyme elevation (bili \> 1,5\*ULN - ASAT \> 2,5\*ULN - ALAT \> 2,5\*ULN) or~* Impaired renal function (creatinine clearance by cockcroft \< 60 cc/min)~* Proteinuria \>1,0gr/24hr~* Tumour stage: M1a and/or tumour length \> 8 cm and/or \> 5 cm radially~* Major surgery within 4 weeks prior to the start of study treatment~* Bleeding disorder~* Known allergy to one of the study drugs used~* Use of any substance known to interfere with the chemotherapy clearance~* Previous radiotherapy to the chest~* Significant concomitant diseases preventing the safe administration of study drugs or likely to interfere with study assessments~* Uncontrolled angina pectoris; cardiac failure or clinically significant arrhythmias~* Continuous use of immunosuppressive agents~* Concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine~* Prior exposure to anti-EGFR targeting agents.~* Hearing loss \> 25 dB under normal~* Neurotoxicity \> CTC grade 1~* Pregnancy or breast feeding~* Patients (M/F) with reproductive potential not implementing adequate contraceptive measures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-operative chemotherapy (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).